MeriMepodib, VI-21497, VX-497

Name	Merimepodib
Synonyms	MMP VX497 VX-497 VX 497 VI21497 VI 21497 VI-21497 VI 21497 Merimepodib MERIMEPODIB MeriMepodib, VI-21497, VX-497 (S)-Tetrahydrofuran-3-yl 3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzylcarbamate [(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate [[3-[[[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]carbamic acid (3S)-tetrahydro-3-furanyl ester Carbamic acid, N-[[3-[[[[3-methoxy-4-(5-oxazolyl)phenyl]amino]carbonyl]amino]phenyl]methyl]-, (3S)-tetrahydro-3-furanyl ester
CAS	198821-22-6

Molecular Formula	C23H24N4O6
Molar Mass	452.46
Density	1.36±0.1 g/cm3(Predicted)
Boling Point	571.4±50.0 °C(Predicted)
Solubility	DMSO: ≥ 31 mg/mL
pKa	11.66±0.46(Predicted)
Storage Condition	Sealed in dry,Room Temperature
In vitro study	VX-497 has antiproliferative effect on lymphoid and keratinocyte cells. The antiproliferative effect of VX-497 in cells is reversed within 48 h of its removal. VX-497 has intermediate antiviral activity against a second group of viruses, which includes HSV-1, parainfluenza-3 virus, BVDV, VEEV, and dengue virus, with IC 50 s ranging from 6 to 19 μM. VX-497 is 100-fold more potent, with an IC 50 of 380 nM and a corresponding CC 50 of 5.2 μM, for a therapeutic index of 14. The antiviral activity of VX-497 in HepG2.2.2.15 cells is reversed threefold by the addition of guanosine.
In vivo study	Oral administration of VX-497 inhibits the primary IgM antibody response in a dose-dependent manner, with an ED 50 value of appr 30-35 mg/kg in mice. Single daily dosing of VX-497 is observed to be as effective as twice-daily dosing in this model of immune activation. GVHD developed in the vehicle-treated allografted F1 mice and treatment with VX-497 improved all manifestations of the disease significantly. The 2.9-fold increase in spleen weight in allografted animals is reduced to a 1.6-fold increase in the VX-497-treated mice. Serum IFN-gamma levels are increased 54-fold in the vehicle group while there is a 7.4-fold increase in VX-497-treated animals.

Last Update：2024-01-02 23:10:35

Spot supply

Product Name: Merimepodib Visit Supplier Webpage Request for quotation
CAS: 198821-22-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409

Wechat: 18301782025

Spot supply

Product Name: Merimepodib Visit Supplier Webpage Request for quotation
CAS: 198821-22-6
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409

Wechat: 18301782025

View History

MeriMepodib, VI-21497, VX-497

MeriMepodib, VI-21497, VX-497 Request for Quotation